Clinical Trial

Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2024 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Atrial fibrillation (AF) is a common arrhythmia, particularly prevalent in the elderly population. Catheter ablation is a common treatment for AF, but post-ablation recurrence of arrhythmias remains a significant clinical challenge. Dapagliflozin, an SGLT2 inhibitor primarily used for the treatment of type 2 diabetes, has shown potential in the field of cardiology, particularly for treating heart failure patients. Some studies suggest that dapagliflozin may reduce cardiac workload, improve heart function, and could even help in the management of atrial fibrillation. Therefore, this study aims to explore whether dapagliflozin can reduce the recurrence of arrhythmias following atrial fibrillation catheter ablation.
Trial Details
NCT Number NCT06740786
Lead Sponsor Xu Liu
Collaborators: Hefei Binhu Hospital, The First People's Hospital of Hefei, Second People's Hospital of Hefei City, The Second People's Hospital of Anhui Province
Conditions Atrial Fibrillation (AF)
Enrollment 250 participants
Start Date 2024-12-10
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-18